Alnylam Pharmaceuticals
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT06679946
- Locations
- 🇬🇧
Clinical Trial Site, Manchester, United Kingdom
A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT06675565
- Locations
- 🇨🇦
Clinical Trial Site, Montreal, Canada
A Study to Evaluate ALN-6400 in Adult Healthy Volunteers
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT06659640
- Locations
- 🇨🇦
Clinical Trial Site, Montreal, Canada
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 158
- Registration Number
- NCT06600321
- Locations
- 🇺🇸
Clinical Trial Site, San Antonio, Texas, United States
🇺🇸MD Anderson, Houston, Texas, United States
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06585449
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06423352
- Locations
- 🇯🇵
Clinical Trial Site, Tokyo, Japan
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06393712
- Locations
- 🇨🇦
Clinical Trial Site, Toronto, Ontario, Canada
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06360289
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU) Le Kremlin-Bicêtre Assistance Publique-Hôpitaux de Paris (APHP), Paris, Île-de-France, France
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 390
- Registration Number
- NCT06272487
- Locations
- 🇬🇧
Clinical Trial Site, Pickering, United Kingdom
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT05761301
- Locations
- 🇨🇦
Clinical Trial Site, Toronto, Canada
© Copyright 2024. All Rights Reserved by MedPath